Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
Reza Shojaei, Executive Leader, Strategic Growth Advisor in Health and Biopharma, shared on LinkedIn:
”Are Hemoglobin Oxygen Carriers (HBOCs) a breakthrough waiting to happen, or just hype?
What if we could deliver oxygen without relying on blood donors, refrigeration, or blood typing?
That’s the bold promise of Hemoglobin Oxygen Carriers (HBOCs), sometimes called “artificial blood.”
Approved in South Africa, tested in Japan, funded by the U.S. military, and eyed for organ preservation in Europe… yet still viewed with caution by regulators.
So, are HBOCs a breakthrough waiting to happen, or just hype?’
In this newsletter edition, we explore:
- Where HBOCs stand today
- Their advantages and safety challenges
- Whether they can truly replace blood donation
- What the global market looks like in 2025
- If they’re viable for low- and middle-income countries”
Read the full Blood and Plasma Pulse newsletter edition here.
Stay updated on the emerging in the field of hematology with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention